Mount Sinai School of Medicine and Medisyn Technologies, Inc. Announce Agreement to Discover Novel Therapeutics for Treating Alzheimer's Disease
Published: Sep 13, 2007
NEW YORK & MINNEAPOLIS--(BUSINESS WIRE)--Mount Sinai School of Medicine (MSSM) and Medisyn Technologies today announced a collaboration for the development of novel ß-amyloid (Aß) lowering drugs as a treatment in Alzheimer’s disease. Starting with MSSM’s previous research data obtained from testing early-stage lead compounds, the collaboration utilizes Medisyn Technologies’ molecular topology Forward Engineering™ platform to build a diverse pipeline of Alzheimer’s disease drug candidates. The goal of the study is to complete in vivo efficacy validation of the novel drug candidates by the end of 2007.